# Sorafenib for Patients With Extensive Keloids

> **NCT01425216** · PHASE2 · TERMINATED · sponsor: **Tirgan, Michael H., M.D.** · enrollment: 60 (estimated)

## Conditions studied

- Keloids

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01425216
- **Lead sponsor:** Tirgan, Michael H., M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** IND application was not approved by the US FDA - Project was never started
- **Last updated:** 2016-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425216, "Sorafenib for Patients With Extensive Keloids". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01425216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*